The process for AcuCort AB (publ)'s application for market approval in the USA for Zeqmelit is in an intensive phase. The company assesses that the dialogue with the FDA is constructive and that there are conditions to submit the application during the second half of 2024. AcuCort received the company's first commercial order for the oral film Zeqmelit®?

at the end of February and plans to start sales in the Nordic region during the summer of 2024. As a result, the company is enhancing preparations for the prioritized potential market in the USA. The FDA, Food and Drug Administration, process has taken longer than previously estimated, which does not prompt any changes in AcuCort's strategy to launch Zeqmelit®?

in the USA.